# Mycophenolate Mofetil in Membranous Nephropathy

> **NCT00135967** · PHASE2,PHASE3 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 30 (—)

## Conditions studied

- Glomerulonephritis, Membranous

## Interventions

- **DRUG:** mycophenolate mofetil orally 1000 mg twice a day (BID)
- **DRUG:** prednisone 0,5 mg/kg orally on alternate days
- **DRUG:** intravenous (i.v.) methylprednisolone 1000 mg, total 9

## Key facts

- **NCT ID:** NCT00135967
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2005-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135967, "Mycophenolate Mofetil in Membranous Nephropathy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00135967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*